Organoid Technology $5.7B Market by 2034 Merck HUB Acquisition 23% CAGR Growth Patient-Derived Organoids Personalized Drug Testing Brain Organoids Organoid Technology $5.7B Market by 2034 Merck HUB Acquisition 23% CAGR Growth Patient-Derived Organoids Personalized Drug Testing Brain Organoids
Growing Organs in a Dish

OrganoidMedicine

Mini-Organs for Personalized Drug Discovery

Organoids are 3D stem cell-derived mini-organs that replicate patient biology. $5.7 billion market by 2034. Merck's HUB Organoids acquisition validated the space. OrganoidMedicine.com owns the therapeutic application of organoid technology.

Acquire This Domain See The Science
STEM CELL PATIENT-DERIVED ORGANOID DRUG RESPONSE PREDICT
The Technology

What is Organoid Medicine?

Organoids are 3D structures grown from patient stem cells that self-organize into mini-organs. They enable personalized drug testing, disease modeling, and regenerative medicine.

Merck Acquires HUB Organoids (Jan 2025)
In January 2025, Merck acquired HUB Organoids, the pioneer of adult stem cell-derived organoid technology founded by Dr. Hans Clevers. This validates the therapeutic potential of organoids for drug discovery and personalized medicine. FDA now accepts organoids as NAMs (New Approach Methodologies) under the Modernization Act.
$5.7B
Market by 2034
23%
CAGR growth rate
80%
Patient tumor match rate
2wk
Time to drug response
Organoid Types

Mini-Organs for Every System

Brain Organoids
Modeling Alzheimer's, Parkinson's, and neurodevelopmental disorders with tau pathology.
Gut Organoids
Intestinal epithelium for IBD research, drug absorption, and microbiome studies.
Liver Organoids
Hepatocyte function for drug metabolism and DILI prediction studies.
Tumor Organoids
Patient-derived cancer models for personalized chemotherapy selection.
Kidney Organoids
Nephron structures for nephrotoxicity screening and PKD modeling.
Retinal Organoids
Photoreceptor structures for macular degeneration and gene therapy.
Industry Leaders

Companies Pioneering Organoid Medicine

HUB Organoids (Merck)
Acquired Jan 2025
Adult stem cell-derived organoids from Hans Clevers lab. Gold standard.
StemCell Technologies
Reagent Leader
Complete organoid culture systems and differentiation media.
Organoid Sciences
Oncology Focus
Patient-derived tumor organoids for personalized cancer treatment.
DefiniGEN
iPSC Platform
Disease-specific organoids from induced pluripotent stem cells.
Cellesce
Scale-Up Tech
Bioreactors for industrial-scale organoid production.
Crown Bioscience
CRO Services
Tumor organoid biobank for preclinical drug testing services.
OrganoidMedicine.com

The Therapeutic Future of Organoids

$5.7B market. Merck acquisition validated. FDA accepts organoids as NAMs. This domain owns the therapeutic application.

Inquire About This Domain
Acquire This Domain

Own Organoidmedicine

This premium domain is available for acquisition. Perfect for companies, startups, or investors in this space.

Submit your inquiry below and we'll respond within 24 hours.